In Silico Screening and In Vivo Evaluation of Potential CACNA2D1 Antagonists as Intraocular Pressure-Reducing Agents in Glaucoma Therapy

Glaucoma is a leading cause of permanent vision loss and current drugs do not halt disease progression. Thus, new therapies targeting different drug targets with novel mechanisms of action are urgently needed. Previously, we identified CACNA2D1 as a novel modulator of intraocular pressure (IOP) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hanxuan, Ibrahim, Mohamed Moustafa, Chen, Hao, Li, Wei, Jablonski, Monica M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466147/
https://www.ncbi.nlm.nih.gov/pubmed/34577587
http://dx.doi.org/10.3390/ph14090887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466147/
https://www.ncbi.nlm.nih.gov/pubmed/34577587
http://dx.doi.org/10.3390/ph14090887

Ejemplares similares